K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo

Activating K-RAS mutations occur at a frequency of 90% in pancreatic cancer, and to date no therapies exist targeting this oncogene. K-RAS signals via downstream effector pathways such as the MAPK and the PI3K signaling pathways, and much effort has been focused on developing drugs targeting compone...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Hofmann, Irmgard, Weiss, Andreas, Elain, Gaelle, Schwaederle, Maria, Sterker, Dario, Romanet, Vincent, Schmelzle, Tobias, Lai, Albert, Brachmann, Saskia M., Bentires-Alj, Mohamed, Roberts, Thomas M., Sellers, William R., Hofmann, Francesco, Maira, Sauveur-Michel
Format: Artigo
Sprog:Inglês
Udgivet: Public Library of Science 2012
Fag:
Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3432074/
https://ncbi.nlm.nih.gov/pubmed/22952903
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0044146
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker